In a report released yesterday, Thomas Shrader from BTIG maintained a Buy rating on Arcturus Therapeutics (ARCT – Research Report), with a price target of $48.00. The company’s shares closed ...
Despite a dip in revenue, Arcturus Therapeutics Holdings Inc (ARCT) focuses on innovation and strategic partnerships to bolster its pipeline and financial position. SAN DIEGO (AP) — Arcturus ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback